卡泊芬净在新生儿真菌治疗中的肝脏安全性研究

doi:10.5246/jcps.2022.11.074

中国药学(英文版) ›› 2022, Vol. 31 ›› Issue (11): 877-882.DOI: 10.5246/jcps.2022.11.074

卡泊芬净在新生儿真菌治疗中的肝脏安全性研究

袁高乐, 涂颖秋^*(), 晏伟伟, 王芳

南昌大学第一附属医院, 江西南昌 330006

收稿日期:2022-07-13 修回日期:2022-08-10 接受日期:2022-09-21 出版日期:2022-11-30 发布日期:2022-11-30
通讯作者: 涂颖秋
作者简介:
+ Tel.: +86-15180131746, E-mail: yingqiu281@163.com

Hepatic safety of caspofungin during treatment of fungal diseases in neonates

Gaole Yuan, Yingqiu Tu^*(), Weiwei Yan, Fang Wang

The First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China

Received:2022-07-13 Revised:2022-08-10 Accepted:2022-09-21 Online:2022-11-30 Published:2022-11-30
Contact: Yingqiu Tu

摘要/Abstract

摘要：

在新生儿中使用卡泊芬净属于超说明用药。因此, 我们进行了一项针对卡泊芬净治疗或预防的23例新生儿念珠菌感染的回顾性研究, 以调查卡泊芬净治疗新生儿真菌疾病期间的肝脏安全性。在接受卡泊芬净治疗的23例新生儿中, 治愈13例(57%), 好转10例(43%)。没有与药物使用相关的不良反应, 如胃肠道、血小板减少和肝功能损害。总而言之, 卡泊芬净治疗或预防新生儿念珠菌感染效果良好, 未发现与使用密切相关的严重不良反应。但在临床实践中应考虑抗真菌药物的经济性和安全性, 以便合理使用。

关键词: 卡泊芬净, 念珠菌感染, 新生儿, 肝功能

Abstract:

The use of caspofungin in neonates is beyond the instructions. Therefore, a retrospective analysis was performed to investigate the hepatic safety of caspofungin during the treatment of fungal diseases in neonates. A retrospective analysis was conducted on 23 neonates with Candida infection who were treated or prevented with caspofungin. Among the 23 neonates treated with caspofungin, 13 cases were cured (57%), and 10 cases showed improvements (43%). In addition, there were no adverse reactions associated with drug use, such as gastrointestinal tract, thrombocytopenia, and liver function damage. In summary, caspofungin achieved good results in the treatment or prevention of Candida infection in neonates, and no severe adverse reactions closely related to its use were found. However, the economy and safety of antifungal drugs should be considered in clinical practice for reasonable use.

Key words: Caspofungin, Candida infection, Neonate, Liver function

Supporting:

袁高乐, 涂颖秋, 晏伟伟, 王芳. 卡泊芬净在新生儿真菌治疗中的肝脏安全性研究[J]. 中国药学(英文版), 2022, 31(11): 877-882.

Gaole Yuan, Yingqiu Tu, Weiwei Yan, Fang Wang. Hepatic safety of caspofungin during treatment of fungal diseases in neonates[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(11): 877-882.

图/表 3

参考文献 13

[1]	Bersani, I.; Piersigilli, F.; Goffredo, B.M.; Santisi, A.; Cairoli, S.; Ronchetti, M.P.; Auriti, C. Antifungal drugs for invasive candida infections (ICI) in neonates: future perspectives. Front. Pediatr. 2019, 7, 375.
[2]	Clerihew, L.; Lamagni, T.L.; Brocklehurst, P.; McGuire, W. Candida parapsilosis infection in very low birthweight infants. Arch. Dis. Child Fetal. Neonatal. Ed. 2007, 92, F127–F129.
[3]	Manzoni, P.; Mostert, M.; Castagnola, E. Update on the management of Candida infections in preterm neonates. Arch. Dis. Child Fetal. Neonatal. Ed. 2015, 100, F454–F459.
[4]	Sun, C.; Zhang, X.Y.; Li, Y.; Ma, S.L. Clinical efficacy and safety of caspofungin in the treatment of neonatal invasive fungal infection. Chin. J. Med. Guide. 2020, 22, 673–676.
[5]	Merck & CO., INC. Caspofungin [package insert]. U.S. Food and Drug Administration website; 2005 February [cited 2020 May 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/ 21227s015lbl.
[6]	Xellia Pharmaceuticals ApS. Caspofunin [product information]. European Medicines Agency website; 2016 February [cited 2020 May 15]. Available from: https://www.ema.europa.eu/en/documents/product-information/caspofungin-accord-epar-product-information_en.
[7]	Product information. Cancidas (caspofungin). Merck and Co., Whitehouse Station, NJ, USA. 2009.
[8]	Hesseling, M.; Weindling, M.; Neal, T. First reported use of caspofungin in an extremely low-birth-weight neonate. J. Matern. Fetal. Neonatal. Med. 2003, 14, 212.
[9]	Wang, F.; Zhang, X.Y. Practical Infectology Therapeutics (3rd edition). Beijing: The People's Health Press. 2020, 1108.
[10]	Sáez-Llorens, X.; Macias, M.; Maiya, P.; Pineros, J.; Jafri, H.S.; Chatterjee, A.; Ruiz, G.; Raghavan, J.; Bradshaw, S.K.; Kartsonis, N.A.; Sun, P.; Strohmaier, K.M.; Fallon, M.; Bi, S.; Stone, J.A.; Chow, J.W. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob. Agents Chemother. 2009, 53, 869–875.
[11]	Yang ,Y.L.; Wu, B.Q. Progress of echinocandin in the treatment of neonatal fungal sepsis. Chin. J. Nosocomial. Infect. 2018, 28, 1436–1440.
[12]	Caudle, K.E.; Inger, A.G.; Butler, D.R.; Rogers, P.D. Echinocandin use in the neonatal intensive care unit. Ann. Pharmacother. 2012, 46, 108–116.
[13]	Pappas, P.G.; Kauffman, C.A.; Andes, D.R.; Clancy, C.J.; Marr, K.A.; Ostrosky-Zeichner, L.; Reboli, A.C.; Schuster, M.G.; Vazquez, J.A.; Walsh, T.J.; Zaoutis, T.E.; Sobel, J.D. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin. Infect. Dis. 2015, 62, e1–e50.

卡泊芬净在新生儿真菌治疗中的肝脏安全性研究

Hepatic safety of caspofungin during treatment of fungal diseases in neonates

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 13

相关文章 0

编辑推荐

Metrics

本文评价